CDMO Argonaut Manufacturing Services launched its aseptic vial filling services program, which is based on the custom Bausch + Ströbel VarioSys® line and designed to maximize the yield of biologics and other high-value drug substances.

“As drug substance values continue to rise, we saw a need in the market for fill/finish service providers to adapt. Our line incorporates technologies designed to maximize yield and minimize risk, in order to safeguard every drop of API,” said Chris Duffy, COO of Argonaut. Key line features include robotics, isolator technology, minimal hold up volume, and in-line nondestructive 100% weight checks.

Added Eric Blair, the company CCO, “We are dedicated to supporting our clients in clinical trials and beyond, and we are honored to have our first clients developing the most innovative therapies. The ADVANCEDFill technology our line features is ideal in the areas of rare disease, orphan drugs, and other small-batch biologics applications. Personalized medicine is driving an industry need for our services, as we have the ability to provide the small batch throughput and near zero-loss yield needed for precious drug substance.”

The new introduction builds upon Argonaut’s existing strengths and capabilities, noted Wayne Woodard, CEO. “I’m incredibly proud of our team of established industry leaders. Argonaut has designed and built our drug product manufacturing services to meet the demanding requirements of the world’s best biopharma companies. Our advanced capabilities match the needs for drug product manufacturing today and for decades to come.”

With the announcement of the launch, Argonaut expects to begin serving clinical phase customers in Q1 2020.

Previous articleFind the Right Fit when Tackling Late Stage Bioprocessing Challenges
Next articleBiopharma 4.0 Must Guard against Cyberattacks